Cholangiocarcinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:70567OMIM:615619C24.8C24.9C22.1
Who is this for?
Show terms as
1FDA treatments85Active trials198Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Clinical phenotype terms— hover any for plain English:

Acholic stoolsHP:0011985Biliary tract neoplasmHP:0100574
Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Dec 2026Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

3D Medicines (Beijing) Co., Ltd. — PHASE2

TrialNOT YET RECRUITING
Mar 2026Cosiporfin Sodium for Injection Photodynamic Therapy

Shanghai Guangsheng Biopharmaceutical Co., Ltd — PHASE2

TrialRECRUITING
Mar 2026Wet Heparinized Suction for Abdominal Cancer

H. Lee Moffitt Cancer Center and Research Institute — NA

TrialNOT YET RECRUITING
Feb 2026Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Tianjin Medical University Cancer Institute and Hospital — PHASE2

TrialNOT YET RECRUITING
Feb 2026A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Elevar Therapeutics — PHASE2

TrialNOT YET RECRUITING
Feb 2026FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Sun Yat-sen University — PHASE2

TrialNOT YET RECRUITING
Jan 2026A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Mehmet Akce — PHASE2

TrialRECRUITING
Jan 2026REGULUS: MRI-guided Adaptive SABR for Liver Cancers

Stanford University — PHASE2

TrialRECRUITING
Jan 2026Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

TransThera Sciences (Nanjing), Inc. — PHASE3

TrialNOT YET RECRUITING
Jan 2026Hepatobiliary and Pancreatic Tumor Biobank

Second Affiliated Hospital, School of Medicine, Zhejiang University

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

PEMAZYRE

Pemigatinib· Incyte CorporationAccelerated Approval
for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as

for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test

Clinical Trials

20 recruitingView all trials with filters →
Other20 trials
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
Actively Recruiting
PI: Hans-Christian Pommergaard, M.D./Ph.D. (Rigshospitalet, Denmark) · Sites: Copenhagen
Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.
Actively Recruiting
· Sites: Pavia, Pavia · Age: 1890 yrs
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
Actively Recruiting
PI: Hong Jae Chon, MD. PhD (CHA University) · Sites: Seongnam-si, Gyeonggi-do · Age: 2099 yrs
Registry for Advanced Endoscopy
Actively Recruiting
PI: Erik von Seth, MD, PhD (Region Stockholm) · Sites: Stockholm · Age: 1899 yrs
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
Actively Recruiting
· Sites: Herlev, Copenhagen · Age: 1899 yrs
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Actively Recruiting
PI: Jia-yan Ni, M.D. (Sun Yat-sem Memorial Hospital, Sun Yat-sen Univers) · Sites: Guangzhou, Guangzhou · Age: 1870 yrs
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Actively Recruiting
PI: Maolin Yan, Doctor (Department of Hepatobiliary Pancreatic Surgery, Fu) · Sites: Fuzhou, Fujian · Age: 1875 yrs
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
Actively Recruiting
PI: Weilin Wang, PHD (Department of Hepatobiliary and Pancreatic Surgery) · Sites: Hangzhou, Zhejiang · Age: 1899 yrs
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
Actively Recruiting
PI: Yonghui Huang (Peking University Third Hospital) · Sites: Beijing, Beijing Municipality; Beijing, Beijing Municipality · Age: 1885 yrs
The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer
Actively Recruiting
· Sites: Seoul · Age: 1899 yrs
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Actively Recruiting
PI: Konstantinos Lazaridis, MD (Mayo Clinic) · Sites: Rochester, Minnesota · Age: 1885 yrs
Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
Actively Recruiting
PI: Marie LEQUOY, MD (AssistancePublique-Hôpitaux de Paris) · Sites: Paris · Age: 1899 yrs
Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)
Enrolling by Invitation
PI: Nguyen H. Tran, MD (Mayo Clinic in Rochester) · Sites: Rochester, Minnesota · Age: 1899 yrs
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma
Actively Recruiting
· Sites: Beijing, Beijing Municipality · Age: 1899 yrs
Liver Transplantation in Intrahepatic Cholangiocarcinoma
Actively Recruiting
PI: Keri E Lunsford, MD, PhD (Rutgers University) · Sites: Newark, New Jersey; Newark, New Jersey · Age: 1889 yrs
Liver Embolization Approaches for Tumor Management
Actively Recruiting
· Sites: Milan · Age: 1899 yrs
Deep Liver Phenotyping and Immunology Study
Actively Recruiting
PI: Rory J Peters (University of Oxford) · Sites: Oxford, Oxfordshire · Age: 1875 yrs
Prospective Evaluation of Biliary Tissue Sampling with ERCP
Enrolling by Invitation
PI: Vinay Chandrasekhara, MD (Mayo Clinic) · Sites: Rochester, Minnesota · Age: 1899 yrs
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
Actively Recruiting
· Sites: Shanghai, Shanghai Municipality · Age: 1890 yrs
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
Actively Recruiting
· Sites: Beijing · Age: 1870 yrs

Specialists

Showing 25 of 198View all specialists →
JY
Jianfeng Yang
SEATTLE, WA
Specialist
PI on 2 active trials823 Cholangiocarcinoma publications
FM
Fei Li, M.D
Specialist
PI on 2 active trials
JM
Junli Wu, MD,PhD
Specialist
PI on 1 active trial
YP
Yi Miao, Prof.
LOS ANGELES, CA
Specialist
PI on 1 active trial
MM
Mohamed O Othman, MD
CLEVELAND, OH
Specialist
PI on 2 active trials
VM
Vinay Chandrasekhara, MD
ROCHESTER, MN
Specialist
PI on 2 active trials
JM
Jishu Wei, MD,PhD
Specialist
PI on 1 active trial
CB
Chiara Braconi
Specialist
3 Cholangiocarcinoma publications
SK
Shahid A Khan
Specialist
4 Cholangiocarcinoma publications
AS
Alphonse E Sirica
Specialist
2 Cholangiocarcinoma publications
LM
Lichun Ma
Specialist
2 Cholangiocarcinoma publications
GG
Gregory J Gores
ROCHESTER, MN
Specialist
2 Cholangiocarcinoma publications
JV
Juan W Valle
ACWORTH, GA
Specialist
4 Cholangiocarcinoma publications
MV
Mathew Vithayathil
Specialist
3 Cholangiocarcinoma publications
LF
Luca Fabris
Specialist
2 Cholangiocarcinoma publications
LG
Lipika Goyal
STANFORD, CA
Specialist
2 Cholangiocarcinoma publications
RK
Robin K Kelley
Specialist
2 Cholangiocarcinoma publications
MC
Massimiliano Cadamuro
Specialist
2 Cholangiocarcinoma publications
SI
Sumera I Ilyas
ROCHESTER, MN
Specialist
2 Cholangiocarcinoma publications
TG
Tim F Greten
BETHESDA, MD
Specialist
2 Cholangiocarcinoma publications
JZ
Jian Zhou
Specialist
PI on 6 active trials3 Cholangiocarcinoma publications
JF
Jia Fan
Specialist
PI on 6 active trials3 Cholangiocarcinoma publications
AM
Andrea Cercek, MD
NEW YORK, NY
Specialist
PI on 3 active trials1 Cholangiocarcinoma publication
DM
Daneng Li, MD
DUARTE, CA
Specialist
PI on 2 active trials

Treatment Centers

8 centers
⚗️ Trial Site

National Institutes of Health Clinical Center

📍 Bethesda, Maryland

👤 Payal P Khincha, M.D.

👤 Christopher Grunseich, M.D.

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

Financial Resources

2 resources
PEMAZYRE(Pemigatinib)Incyte Corporation

Blenoxane

Bristol-Myers Squibb Pharmaceutical Research Institute

Blenoxane Patient Support (BMS Access Support)

Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to Cholangiocarcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open CholangiocarcinomaForum →

No community posts yet. Be the first to share your experience with Cholangiocarcinoma.

Start the conversation →

Latest news about Cholangiocarcinoma

Disease timeline:

New recruiting trial: HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: Biliary Dilatation National Special Disease Cohort in China

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: A Clinicobiological Database in Metastatic Digestive Cancers

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: Efficacy and Safety of Surgical Treatment for Type IVa CBD

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: A Prospective Clinical Study Using an Artery-first Intermediate Approach in Robot-assisted Pancreaticoduodenectomy

A new clinical trial is recruiting patients for Cholangiocarcinoma

New recruiting trial: The Application of Digital Intelligent Diagnostic and Therapeutic Technology in Biliary Dilation Diagnosis

A new clinical trial is recruiting patients for Cholangiocarcinoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Cholangiocarcinoma

Are there clinical trials for Cholangiocarcinoma?

Yes — 20 recruiting clinical trials are currently listed for Cholangiocarcinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Cholangiocarcinoma?

25 specialists and care centers treating Cholangiocarcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Cholangiocarcinoma?

2 patient support programs are currently tracked on UniteRare for Cholangiocarcinoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.